Skip Navigation


NDT Advance Access originally published online on June 13, 2008
Nephrology Dialysis Transplantation 2008 23(9):3033; doi:10.1093/ndt/gfn342
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/9/3033    most recent
gfn342v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jelkmann, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jelkmann, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


‘O’, erythropoietin carbamoylation versus carbamylation

E-mail: jelkmann@physio.uni-luebeck.de

The first 10% of the full text of this article appears below.

Sir,

Kitamura and co-workers [1] have convincingly shown that recombinant human erythropoietin (rhEPO) and a nonerythropoietic derivative thereof are protective against tubulointerstitial injury in rats with unilateral ureteral obstruction. Indeed, the past . . . [Full Text of this Article]

Wolfgang Jelkmann

Institute of Physiology, University of Luebeck, Luebeck, Germany


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?